GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Cyclically Adjusted FCF per Share

TG Therapeutics (STU:NKB2) Cyclically Adjusted FCF per Share : €-1.56 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

TG Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.052. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.56 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 38.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of TG Therapeutics was 53.20% per year. The lowest was 22.20% per year. And the median was 42.65% per year.

As of today (2024-05-27), TG Therapeutics's current stock price is €15.288. TG Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-1.56. TG Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


TG Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for TG Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Cyclically Adjusted FCF per Share Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.08 -2.78 -1.28 -1.39 -1.51

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.52 -1.51 -1.59 -1.51 -1.56

Competitive Comparison of TG Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



TG Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.052/131.7762*131.7762
=-0.052

Current CPI (Mar. 2024) = 131.7762.

TG Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.080 100.560 -0.105
201409 -0.183 100.428 -0.240
201412 -0.315 99.070 -0.419
201503 -0.200 99.621 -0.265
201506 -0.241 100.684 -0.315
201509 -0.199 100.392 -0.261
201512 -0.246 99.792 -0.325
201603 -0.311 100.470 -0.408
201606 -0.235 101.688 -0.305
201609 -0.273 101.861 -0.353
201612 -0.328 101.863 -0.424
201703 -0.392 102.862 -0.502
201706 -0.377 103.349 -0.481
201709 -0.294 104.136 -0.372
201712 -0.277 104.011 -0.351
201803 -0.322 105.290 -0.403
201806 -0.394 106.317 -0.488
201809 -0.362 106.507 -0.448
201812 -0.376 105.998 -0.467
201903 -0.364 107.251 -0.447
201906 -0.366 108.070 -0.446
201909 -0.337 108.329 -0.410
201912 -0.286 108.420 -0.348
202003 -0.534 108.902 -0.646
202006 -0.347 108.767 -0.420
202009 -0.403 109.815 -0.484
202012 -0.345 109.897 -0.414
202103 -0.519 111.754 -0.612
202106 -0.379 114.631 -0.436
202109 -0.432 115.734 -0.492
202112 -0.581 117.630 -0.651
202203 -0.464 121.301 -0.504
202206 -0.345 125.017 -0.364
202209 -0.257 125.227 -0.270
202212 -0.164 125.222 -0.173
202303 -0.399 127.348 -0.413
202306 -0.274 128.729 -0.280
202309 0.503 129.860 0.510
202312 -0.078 129.419 -0.079
202403 -0.052 131.776 -0.052

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


TG Therapeutics  (STU:NKB2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


TG Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics (STU:NKB2) Business Description

Industry
Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines